The estimated Net Worth of Rita M O'connor is at least $639 millier dollars as of 15 March 2022. Ms connor owns over 13,700 units of PLx Pharma stock worth over $1,067 and over the last 6 years she sold PLXP stock worth over $0. In addition, she makes $638,125 as CFO and Head of Manufacturing & Supply Chain at PLx Pharma.
Ms has made over 3 trades of the PLx Pharma stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 13,700 units of PLXP stock worth $50,142 on 15 March 2022.
The largest trade she's ever made was buying 13,700 units of PLx Pharma stock on 15 March 2022 worth over $50,142. On average, Ms trades about 3,334 units every 72 days since 2019. As of 15 March 2022 she still owns at least 26,670 units of PLx Pharma stock.
You can see the complete history of Ms connor stock trades at the bottom of the page.
Rita M. O'Connor CPA, CPA is the CFO and Head of Manufacturing & Supply Chain at PLx Pharma.
As the CFO and Head of Manufacturing & Supply Chain of PLx Pharma, the total compensation of Ms CPA at PLx Pharma is $638,125. There are 2 executives at PLx Pharma getting paid more, with Natasha Giordano having the highest compensation of $912,328.
Ms CPA is 53, she's been the CFO and Head of Manufacturing & Supply Chain of PLx Pharma since . There are 10 older and 2 younger executives at PLx Pharma. The oldest executive at PLx Pharma Inc. is Patrick M. Lonergan, 86, who is the Member of Chief Exec. Officer Advisory Group.
Rita's mailing address filed with the SEC is 9 FISHERS LANE, SUITE E, SPARTA, NJ, 07871.
Over the last 8 years, insiders at PLx Pharma have traded over $0 worth of PLx Pharma stock and bought 841,160 units worth $2,548,334 . The most active insiders traders include West Asset Management Llc Park, Michael J Valentino et David Emerson Jorden. On average, PLx Pharma executives and independent directors trade stock every 124 days with the average trade being worth of $2,403. The most recent stock trade was executed by Natasha Giordano on 15 March 2022, trading 4,100 units of PLXP stock currently worth $14,965.
PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.
PLx Pharma executives and other stock owners filed with the SEC include: